FDA acts to expand access to COVID-19 therapy

The Food and Drug Administration recently issued an enforcement policy allowing certain modifications to expand the availability of devices used in extracorporeal membrane oxygenation therapy during the COVID-19 public health emergency. The policy will allow for device modification without requiring certain premarket notifications and applications, where such modification does not create an undue risk.